U.S. Digital Therapeutics Market Updates : to Grow at a CAGR of 19.2% from 2020 to 2027

Allied Market Research published a report, titled, "U.S. Digital Therapeutics Market by Application (Diabetes, Obesity, Cardiovascular Disease (CVD), Central Nervous System (CNS) Disease, Respiratory Disease, Smoking Cessation, Gastrointestinal Disorder (GID), and Others), Product (Software and Device), and Sales Channel (Business-to-Business(B2B), Business-to-Consumer (B2C)): Opportunity Analysis and Industry Forecast, 2020-2027." According to the report, the U.S. digital therapeutics industry generated $1.16 billion in 2019, and is estimated to generate $5.08 billion by 2027, growing at a CAGR of 19.2% from 2020 to 2027.

The U.S. digital therapeutics market is experiencing significant growth driven by increased adoption of tablets, smartphones, and smart wearables, alongside healthcare apps. This surge is fueled by the need to reduce healthcare costs and the embrace of technologically advanced healthcare solutions. However, concerns about data privacy and inadequate reimbursement policies are hindering market expansion. Nonetheless, supportive regulations and increased investments offer promising opportunities in the future.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐑𝐞𝐩𝐨𝐫𝐭- https://www.alliedmarketresearch.com/request-sample/7066

In terms of applications, diabetes holds the largest market share, thanks to its high prevalence and cost-effective treatment options. Yet, the obesity segment is poised for the fastest growth due to rising overweight populations and the availability of digital therapeutics for dietary management and activity tracking. Software dominates the market and is expected to maintain its lead, driven by demand for cost reduction and innovative features promoting health management.

Regarding sales channels, business-to-business transactions currently dominate, fueled by companies offering favorable reimbursement policies to employees. However, business-to-consumer channels are anticipated to grow rapidly, facilitated by the accessibility of software and devices, as well as increasing demand from patients and caregivers.

𝐊𝐞𝐲 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬 𝐅𝐨𝐫 𝐒𝐭𝐚𝐤𝐞𝐡𝐨𝐥𝐝𝐞𝐫𝐬
This report provides a detailed quantitative analysis of the current U.S. digital therapeutics market trends and forecast estimations from 2020 to 2027, which assists to identify the prevailing market opportunities.

An in-depth market analysis includes analysis of various regions, which is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate country-specific plans.

A comprehensive analysis of factors that drive and restrain growth of the market is provided.

Country-wise market conditions are comprehensively analyzed in this report.
The projections in this report are made by analyzing the current trends and future market potential from 2020 to 2027, in terms of value.

An extensive analysis of the market provides insights that are expected to allow companies to strategically plan their business moves.

Key market players within the U.S. digital therapeutics market are profiled in this report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of the market.

𝐊𝐞𝐲 𝐅𝐢𝐧𝐝𝐢𝐧𝐠𝐬 𝐎𝐟 𝐓𝐡𝐞 𝐒𝐭𝐮𝐝𝐲
Software is expected to be one of the most lucrative segments, registering a CAGR of 20.3% during the forecast period.

The business-to-business (B2B) segment accounted for maximum share in the U.S. digital therapeutics market in 2019, and is expected to grow at a CAGR of 18.8% during the forecast period.

Based on business-to-consumers (B2C) segment, the patients segment is expected to project with the highest CAGR throughout the forecast period.

By application, the diabetes segment generates the largest revenue in 2019, and is anticipated to continue this trend during the forecast period.

𝐒𝐩𝐞𝐚𝐤 𝐭𝐨 𝐎𝐮𝐫 𝐀𝐧𝐚𝐥𝐲𝐬𝐭 https://www.alliedmarketresearch.com/connect-to-analyst/A06701

𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐦𝐚𝐫𝐤𝐞𝐭 𝐩𝐥𝐚𝐲𝐞𝐫𝐬
2MORROW, Inc.
Fitbit, Inc. (Twine Health, Inc.)
Livongo Health, Inc.
Medtronic Plc.
Omada Health, Inc.
Pear Therapeutics, Inc.
Proteus Digital Health, Inc.
Resmed, Inc. (Propeller Health)
Voluntis, Inc.
Welldoc, Inc.

𝐊𝐧𝐨𝐰 𝐌𝐨𝐫𝐞- https://www.alliedmarketresearch.com/us-digital-therapeutics-market-A06701

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.